Show simple item record

dc.contributor.authorChapman, PB
dc.contributor.authorRobert, C
dc.contributor.authorLarkin, J
dc.contributor.authorHaanen, JB
dc.contributor.authorRibas, A
dc.contributor.authorHogg, D
dc.contributor.authorHamid, O
dc.contributor.authorAscierto, PA
dc.contributor.authorTestori, A
dc.contributor.authorLorigan, PC
dc.contributor.authorDummer, R
dc.contributor.authorSosman, JA
dc.contributor.authorFlaherty, KT
dc.contributor.authorChang, I
dc.contributor.authorColeman, S
dc.contributor.authorCaro, I
dc.contributor.authorHauschild, A
dc.contributor.authorMcArthur, GA
dc.date.accessioned2020-12-17T04:38:17Z
dc.date.available2020-12-17T04:38:17Z
dc.date.issued2017-10-01
dc.identifier.citationChapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., Dummer, R., Sosman, J. A., Flaherty, K. T., Chang, I., Coleman, S., Caro, I., Hauschild, A. & McArthur, G. A. (2017). Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. [Abstract]. ANNALS OF ONCOLOGY, 28 (10), pp.2581-2587. https://doi.org/10.1093/annonc/mdx339.
dc.identifier.issn0923-7534
dc.identifier.urihttp://hdl.handle.net/11343/255396
dc.publisherOXFORD UNIV PRESS
dc.titleVemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
dc.typeAbstract
dc.identifier.doi10.1093/annonc/mdx339
melbourne.affiliation.departmentMelbourne Medical School
melbourne.source.titleAnnals of Oncology
melbourne.source.volume28
melbourne.source.issue10
melbourne.source.pages2581-2587
melbourne.elementsid1255195
melbourne.contributor.authorMcArthur, Grant
dc.identifier.eissn1569-8041
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record